Abstract
Despite the large increase in diseases involving the central nervous system (CNS) in recent decades, drug availability is still low. The major limitation is the permeation of drugs through the blood-brain barrier (BBB) to reach the site of therapeutic action. A strategy to overcome the limitation of drug delivery through the BBB is the use of biomimetic vesicles, with potential for target…